FindTrial
Sign In

An observational study to determine the outcome of the initiating oral spironolactone in the treatment of chronic central serous retinopathy.

A study of efficacy and predictive factors of oral Spironolactone treatment in Chronic Central Serous Retinopathy. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/092403
Enrollment
90
Registered
2025-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H357- Separation of retinal layers

Interventions

Intervention1: Nil: Nil

Sponsors

SMS Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient giving informed written consent. Age group 18 to 50 yrs. Chronic Central Serous Retinopathy. Resolution of edema after treatment of Tab Spironolactone.

Exclusion criteria

Exclusion criteria: Patients with any other macular pathology. Patients with previous photocoagulation laser within one year. Patients with Injection Anti Vascular Growth Factors within one year. Patients with any contraindication to oral Spironolactone such as kidney or liver disease. Patients already taking Tab Spironolactone for some other cause.

Design outcomes

Primary

MeasureTime frame
TO study predictive factors for positive response to oral spironolactone treatment among cases of chronic CSR.Timepoint: 1 week, 1 month, 3 months—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Nagendra Shekhawat

Sawai Man Singh Medical College

drnshekhawat@yahoo.com9414138567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026